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Prostaglandin E (PGE)2 is a major arachidonic acid metabolite
in a wide variety of tissues and is implicated in the control of
inflammatory as well as physiological responses. At least
three major forms of PGE synthase (PGES) have recently been
cloned and characterized: membrane-associated PGES
(mPGES)-1, mPGES-2, and cytosolic PGES (cPGES). Among
them, mPGES-1 is highly inducible by cytokine and is critically
involved in pain and inflammatory responses. Emerging
evidence suggests that mPGES-1 may also participate in
blood pressure (BP) regulation through an impact on renal
and vascular functions. Within the kidney, mPGES-1
predominates in the distal nephron where its expression is
highly inducible by salt loading. Mice lacking mPGES-1
exhibit blunted natriuretic response paralleled with
remarkably suppressed nitric oxide production, leading to
salt-sensitive hypertension. These mice also exhibit an
exaggerated hypertensive response to angiotensin II
infusion. Together, these results suggest that mPGES-1 may
be an important physiological regulator of BP.
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The E series of prostaglandins (PGEs) are the major products
of arachidonic acid metabolism and are implicated in a wide
variety of physiological and pathological processes. PGE2 is a
major mediator of inflammation and is also a key player in the
control of various physiological functions.1 The biosynthesis of
PGE2 requires three sequential steps of the cyclooxygenase
(COX) pathway: the release of arachidonic acid from
membrane glycerophospholipids by phospholipase A2, con-
version of arachidonic acid into the unstable intermediate
PGH2 by COX-1 or -2, and isomerization of PGH2 to PGE2 by
PE synthase (PGES).2,3 The activity of PGES has been detected
in both cytosolic and microsomal fractions of various cells. To
date, at least three major forms of PGES have been cloned and
characterized.3 They are designated as membrane-associated
PGES (mPGES)-1, mPGES-2, and cytosolic PGES (cPGES).
These isoforms of PGES represent products of three distinct
genes with marked differences in enzymatic properties, modes
of expression, and cellular and subcellular localizations,
suggesting distinct functions.3
The first PGES (now referred to as mPGES-1) was cloned
from human cells as microsomal glutathione S-transferase 1-
like 1 whose PGE synthesis activity was dependent on
glutathione.4 This was followed by the isolation of the mouse,
rat, and zebrafish homologs.5–8 mPGES-1 is a member of the
membrane-associated proteins in eicosanoids and glu-
tathione metabolism superfamily, which also contains 5-
lipoxygenase-activating protein and leukotrane C4 synthase.6
The enzyme is a 16-kDa membrane-bound protein encoded
by a 2.0-kb transcript. Like COX-2, mPGES-1 expression in
inflammatory cells is highly inducible by proinflammatory
stimuli. Several recent studies employing mPGES-1-deficient
mice demonstrate a major role of mPGES-1 in pain and
inflammatory responses.9,10 By contrast, the physiological
function of this enzyme has been studied in much less detail.
Recent evidence from our group suggests that mPGES-1 may
play an important role in facilitating renal salt excretion as
well as in modulating the response to angiotensin (Ang) II.11
mPGES-2 is a second mPGES that was originally purified
from bovine heart and subsequently cloned.12,13 It is a
43-kDa protein containing a unique N-terminal hydrophobic
domain, which determines the association with Golgi
membrane. This enzyme is constitutively expressed in various
cells and is considered to be functionally coupled with COX-1
and -2.
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cPGES was originally identified from rat brain as a
cytosolic glutathione-dependent PGES. It was identical to
p23, which is a steroid hormone receptor/hsp90-associated
protein.14 The enzyme was constitutively expressed in the
cytosol in a wide variety of cells and tissues and was unaltered
by proinflammatory stimuli except that it was induced in rat
brain following lipopolysaccharide treatment. The fact that
cPGES and COX-1 are colocalized to the cytosol and also
share the same constitutive properties favors a functional
coupling between the two enzymes.
RENAL EXPRESSION OF mPGES-1
mPGES-1 is abundantly expressed in the kidney with a
substantially higher level in the renal medulla than in renal
cortex,15 a pattern similar to COX-1 and -2.16 A significant
number of published studies using immunohistochemistry,
in situ hybridization, and reverse transcriptase-polymerase
chain reaction on microdissected nephron segments all
consistently documented the predominant expression of
mPGES-1 in the whole collecting duct (CD) system of
mouse,17 rat,18 and rabbit.19 Within the CD, the immunor-
eactive labeling was restricted to the principle but not
intercalated cells.19 This corresponds to the observations that
the CD possesses the greatest rate of PGE2 synthesis of any
segment along the nephron and that there are well-
established inhibitory effects of PGE2 on Na
þ and water
transport in the CD.20 Double labeling studies using in situ
hybridization and immunostaining demonstrated that
mPGES-1 predominantly colocalizes with COX-1 in the
CD, suggesting a functional coupling between the two
enzymes in the distal nephron. In line with this notion,
mPGES-1- and COX-1-deficient mice both develop hyper-
tension when fed a high-salt diet.11,21 A low level of mPGES-1
expression was inconsistently found in renal medullary
interstitial cells11,15,19 where COX-2 is abundantly expressed.
This makes less likely that mPGES-1 couples with COX-2-
mediating PGE2 synthesis in renal medullary interstitial
cells. This statement is not necessarily inconsistent with the
notion that COX-2-derived prostanoids may be important
regulators of BP during high salt intake.21 It is possible that
COX-2 may be linked with other PGES isoforms (e.g., cPGES
or mPGES-2) than mPGES-1 to sustain PGE2 synthesis in
renal medullary interstitial cells in response to high salt
loading.
Emerging evidence suggests that mPGES-1 expression in
the CD is further upregulated in response to chronic salt
loading.11 In this study, the total abundance of mPGES-1
protein, as determined by immunoblotting, significantly
increased in both cortex and the inner medulla following a
7-day high-salt diet. The increased expression was restricted
to the CD as determined by immunostaining. In primary CD
cells, hypertonic NaCl exerted a direct stimulatory effect on
mPGES-1 expression. The ion-substitution experiments
demonstrated that the stimulation was mediated by extra-
cellular Cl and not Naþ . In general, these results suggest a
physiological role of mPGES-1 in the CD.
The macula densa is a specialized cell type critically
important for transducing the signal from the luminal
electrolyte concentration to the afferent arterioles. There is
mounting evidence that COX-2-derived PGE2 participates in
the signaling transduction in the macula densa. Therefore,
attempts have been made to link this phenomenon with
mPGES-1. Subsequently, mPGES-1 expression was detected in
the macula densa in the rabbit kidney by both immunohis-
tochemistry and in situ hybridization despite some variations
in the expression levels in different reports.15,19 Furthermore,
mPGES-1 expression in the macula densa was responsive to
the known stimuli for COX-2, including salt depletion and
Ang-converting enzyme inhibition.19 In general agreement
with this finding, mPGES expression was induced in parallel
with COX-2 in the macula densa in children with Bartter’s
syndrome.22 Together, these studies suggest a possibility that
mPGES-1 may functionally couple with COX-2 in the macula
densa control of renin secretion. However, this notion is
inconsistent with several other studies, which failed to detect
mPGES-1 expression in the macula densa. In this regard,
neither immunostaining nor in situ hybridization studies were
able to detect the signal in the macula densa in the mouse
kidney.11,17 mPGES-1 mRNA was also undetectable in
microdissected glomerulus with attachment of the macula
densa from Sprague–Dawley rats although this preparation
contained abundant signals of COX-2 and Naþ -Kþ -2Cl
cotransporter.18 It is unclear whether differences in species or
sensitivities of the detection systems could account for the
disparities among different reports. This calls for a need for
further clarification of the expression and function of
mPGES-1 in the macula densa cells.
In contrast to the detailed analysis of mPGES-1 expression
in the kidney, the expression of the other two isoforms of
PGES is relatively less studied. By in situ hybridization,
mPGES-2 mRNA was detected in substantially higher levels
in the renal cortex than in the renal medulla in the mouse
kidney and by immunohistochemistry mPGES-2 protein was
ubiquitously expressed along the nephron except that it was
detected at much lower levels in the glomeruli.23 The renal
expression of cPGES was studied only by in situ hybridization
and the signal was diffusely expressed in all nephron
segments.24 The diffused expression patterns of mPGES-2
and cPGES are apparently different from the localized
distribution of COX-1 and -2 in the kidney. Therefore, the
functional roles of mPGES-2 and cPGES in the kidney still
remain elusive.
mPGES-1 AND BP
PGE2 is an important autocrine/paracrine factor that
contributes to sodium balance and BP control through
mechanisms that primarily involve the regulation of renal
excretory function and vasculature tone.1 Recently, mPGES-1
has been identified in the renal distal nephron and the
vasculature. These findings raise a possibility that mPGES-1
may participate in BP regulation through an influence on
renal and vascular functions. To examine this possibility,
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mPGES-1 / mice were placed on a 7-day high-salt diet
plus saline as drinking fluid and mean arterial pressure was
monitored by telemetry. Following chronic salt loading, the
/ mice developed more severe hypertension as compared
to the þ /þ controls (Figure 1a). This result is consistent
with the observation that the / mice exhibited an
impaired ability to excrete a sodium load in both acute and
chronic settings.11 It is highly possible that the abnormal salt
handling accounts for the hypertensive phenotype. Given the
nature of systemic deletion of the mPGES-1 gene, the site of
action of mPGES-1 still cannot be determined. However,
several lines of evidence point to the distal nephron. First, the
induction of mPGES-1 in response to high salt loading was
restricted in the entire CD system but not other nephron
segments. Second, the CD is well known to be a major site of
both production and action of PGE2. These findings indicate
an autocrine mode of action of mPGES-1 in the distal
nephron. mPGES-1 may also act in a paracrine manner in
which PGE2 produced from the CD may modulate the
transport function in the thick ascending limb and may also
augment local blood flow by dilating the smooth muscle cells
of vasa recta. Our results, however, are somewhat incon-
sistent with the report by Cheng et al.25 who were unable to
observe an elevated BP in mPGES-1 knockout mice on a
high-salt diet. It is unclear whether differences in experi-
mental protocols or genetic backgrounds may account for the
disparities between the two studies.
In line with the notion that PGE2 functions as a natriuretic
factor in the distal nephron, chronic salt loading is reported
to increase renal synthesis of PGE2. In the 1970s, an acute
saline infusion was shown to increase prostaglandin-like
materials in renal venous blood and medulla of canine
kidney.26 In the 1980s, a significant number of studies in
rodents quite consistently showed that chronic salt loading
elevated urinary excretion and renal medullary production of
PGE2.
21,27,28 The source and mechanisms of increased renal
synthesis of PGE2 during high salt intake have puzzled the
field for more than 30 years. There is even a debate that
increased urinary PGE2 excretion during high salt loading
might be related to increased urine flow. This issue has been
partially resolved by the experiments employing mPGES-1
/ mice which exhibit a remarkable blockade of high salt-
induced urinary PGE2 excretion.
11 The almost exclusive
localization of high salt-induced mPGES-1 expression in the
CD indicates that the increased renal PGE2 synthesis may
occur primarily in the distal nephron via mPGES-1.
The biological action of PGE2 is mediated by G protein-
coupled E-prostanoid receptors designated EP1, EP2, EP3,
and EP4.
29 These four subtypes of EP receptor couple to
distinct signaling pathways. In general, the EP1 receptor
signals via intracellular Ca2þ and phosphatidylinositol–bi-
sphosphate hydrolysis, whereas the EP2 and EP4 receptors are
coupled to Gs and signal by intracellular cyclic adenosine
monophosphate. The EP3 receptor is more complex in that it
exists in multiple slice isoforms which display differential
coupling to distinct signaling mechanisms via Gi (inhibition
of cyclic adenosine monophosphate formation), Gs (stimula-
tion of cyclic adenosine monophosphate formation), and Gq
(stimulation of intracellular Ca2þ release). Specific EP
receptors mediating the natriuretic action of mPGES-1-
derived PGE2 still remains elusive. The EP1 receptor mRNA is
detected predominantly in the CD where activation of this
receptor inhibits sodium and water reabsorption via a Ca2þ -
coupled mechanism. This evidence favors the EP1 as a
candidate EP receptor responsible for the well-documented
natriuretic and diuretic effects of PGE2. However, this notion
is somewhat incompatible with a recent finding that mice
lacking the EP1 exhibit reduced but not enhanced urine-
concentrating capability.30 The EP4 receptor is primarily
expressed in the glomerulus and according to some, but not
all, studies is found in the CD. Despite evidence for a
potential role of EP4 receptor in furosemide-induced
natriuretic and diuretic responses,31 a specific role of this
receptor in the CD remains elusive. The EP3 receptor is
abundantly expressed in the renal medulla and the CD and
mice lacking the EP3 exhibit normal urinary concentrating
function. Together, the net in vivo contribution of these three
EP receptors to the control of sodium balance and BP is
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Figure 1 | Phenotype of mPGES-1 KO mice on a high salt diet.
Daily (a) mean arterial BP (MAP), (b) urinary excretion of nitrate/
nitrite, and (c) cyclic guanosine monophosphate (cGMP) in mPGES-1
þ /þ (wild-type (WT)) and / (knockout (KO)) mice on a 7-day
high-salt diet. MAP was determined by telemetry, urinary nitrate/
nitrite by the Griess method, and urinary cGMP by enzyme-linked
immunosorbent assay. (a) P¼ 0.045; (b) P¼ 0.0003; (c) Po0.0001
(analysis of the interaction (time strain) by repeated measures
analysis of variance) (figure modified from Jia et al.11).
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unclear and awaits analysis of the respective EP knockout
mice challenged with salt loading. The EP2 predominates in
the vasculature but not the CD, and mice lacking this
receptor develop salt-sensitive hypertension, a phenotype
similar to mPGES-1 knockout mice. These results suggest
that the EP2 may in part mediate the natriuretic and
antihypertensive action of mPGES-1-derived PGE2. The
results also indicate a possible paracrine mode of action of
PGE2 in which mPGES-1-derived PGE2 is released from the
CD and acts on the EP2 in the blood vessels.
Further evidence in support of the role of mPGES-1 in BP
regulation came from the observation that mPGES-1 /
mice develop an exaggerated hypertensive response to
chronic Ang II infusion as compared with wild-type
controls.11 This finding may indicate the vascular action of
mPGES-1. In line with this notion, this enzyme has been
detected in the vasculature both in vivo and in vitro despite
some discrepancies regarding its presence in vascular smooth
muscle versus endothelial cells. As compared with the well-
recognized vasodilatory action of prostacyclin, the vascular
effects of PGE2 have not been well appreciated. This is
partially due to the fact that PGE2 can be either vasodilatory
or vasoconstrictory depending on the activation of distinct
EP receptors and the net in vivo effect of PGE2 might become
unpredictable. The hypertensive phenotype of mPGES-1 /
mice in the setting of Ang II infusion represents an in vivo
evidence for the overall vasodilatory and antihypertensive
function of endogenous PGE2.
mPGES-1 AND NO
Within the kidney, the renal medulla has the greatest capacity
for synthesis of PGs and nitric oxide (NO), the two
important regulators of distal tubular fluid reabsorption. In
line with this notion, the two isoforms of COX (COX-1 and -
2) and the three isoforms of nitric oxide synthase (NOS)
(neuronal NOS, inducible NOS, and endothelial NOS) are all
predominantly expressed in the renal medulla where most of
these enzymes except COX-1 can be induced by a high-salt
diet. Functional studies indicate that renal medullary PGs21,32
and NO33,34 exert similar natriuretic and diuretic effects to
stabilize BP during salt loading. The interaction has also been
demonstrated in renal hemodynamic responses to bradyki-
nin, norepinephrine, and Ang II.35,36 If operation of a renal
medullary depressor–natriuretic mechanism relies on the
action of both PGs and NO, the question arises as to how the
actions of these two autocrine/paracrine factors are coordi-
nated. Existing literature indicates a mutual interaction
between the two pathways. It is well documented that NO
exerts a direct stimulatory effect on PGE2 synthesis in a
variety of cell types mostly through a COX-2-dependent
mechanism. NO can activate COX-2 at levels of gene
expression as well as enzyme activity. On the other hand,
evidence demonstrates that PGE2 stimulates NO formation,
mostly in nonrenal cells. In this regard, PGE2 augments
neuronal NOS and endothelial NOS activities at post-
translational levels in the spinal cord37 and in cultured
human vein endothelial cells,38 respectively. The mutual
interaction of PGE2 and NO has been observed in renal cells
as well, especially in the CD cells where NO stimulates COX-
2 expression and PGE2 release through mitogen-activated
protein kinases39,40 while PGE2 enhances cytokine-induced
NO formation probably through cyclic adenosine monopho-
sphate.41 These in vitro studies indicate that the two signaling
pathways might be mutually stimulatory in the distal
nephron as in other nonrenal cells.
A breakthrough has been made in understanding the
in vivo relationship between PGE2 and NO using mPGES-1
/ mice.11 As expected, chronic high salt loading gradually
and significantly increased urinary nitrate/nitrite excretion in
mPGES-1 þ /þ mice with a maximal increase of 15-fold on
day 7. In a sharp contrast, this increase was not seen in
mPGES-1 / mice and urinary nitrate/nitrite excretion in
these animals was even suppressed to undetectable levels after
3 days of high salt loading (Figure 1b). This result was further
confirmed by measurement of urinary cyclic guanosine
monophosphate (Figure 1c). Together, these findings reveal
a linear relationship between PGE2 and NO in the kidney at
least in the setting of chronic salt loading. The precise
location for PGE2-dependent NO production under this
condition is unknown but evidence points to the distal
nephron. In this regard, the induction of renal mPGES-1
expression in response to high salt loading was restricted to
the CD. Furthermore, high salt-induced expression of
neuronal NOS, a major NO-producing enzyme in the CD
was almost completely abolished in mPGES-1 / mice.
These findings indicate that PGE2 may regulate sodium and
water transport in the CD via NO (Figure 2). The EP receptor
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Figure 2 | Schematic illustration of mechanisms of renal tubular
and vascular effects of mPGES-1-derived PGE2. In response to salt
loading, mPGES-1 couples with COX-1, mediating increased PGE2
synthesis in the CD. The released PGE2 can bind to G-protein-coupled
EP receptors such as EP1, EP3, and EP4 in the CD, activating neuronal
NOS and inducible NOS that produce NO that inhibits Naþ and water
transport. PGE2 can also act on EP2/EP4 receptors in the neighboring
blood vessels to augment local blood flow. VR, vasa recta.
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subtype responsible for stimulation of NO formation in the
CD still remains elusive. Among the four EP receptor
subtypes, the EP1 is well known to mediate the tubular
effects of PGE2 via elevation of intracellular Ca
2þ . Whether
or not the EP1-elicited calcium signaling in the CD is linked
to NO is unclear.
In summary, mPGES-1 has an established role in pain and
inflammatory responses and emerging evidence suggests that
this enzyme is also involved in the maintenance of normal BP.
mPGES-1 is predominantly expressed in the distal nephron
and is further upregulated by a high-salt diet, representing a
major source of high salt-induced PGE2 synthesis. This
enzyme helps stabilize BP by facilitating renal sodium
excretion through a mechanism involving stimulation of
NO synthesis. These results provide a new insight into the
interaction of PGE2 and NO in BP regulation.
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